Treatment outcomes for multidrug- and rifampicin-resistant tuberculosis in Central and West Africa: a systematic review and meta-analysis

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperReviewResearchpeer-review

  • Asbjørn Langeland Toft
  • ,
  • Victor Næstholt Dahl
  • Armando Sifna, Bandim Health Project
  • ,
  • Olusoji Mayowa Ige, Univ Coll Hosp, University College Hospital, Ibadan, University of Ibadan
  • ,
  • Valérie Schwoebel, Independent Consultant. Formerly: EuroTB & International Union Against Tuberculosis and Lung Disease (The Union)
  • ,
  • Mahamadou Bassirou Souleymane, Damien Foundation
  • ,
  • Alberto Piubello, Damien Foundation
  • ,
  • Christian Wejse

OBJECTIVES: We aimed to investigate published data on treatment outcomes of MDR/RR-TB in Central and West Africa as these, to our knowledge, are sparsely available.

METHODS: Systematic review and meta-analysis RESULTS: 14 studies were included representing 4268 individuals in 14 of the 26 countries. Using a random-effects model meta-analysis, we observed a pooled success rate of 80.8% [95%CI 56.0-93.3] for the Central African subgroup and 69.2% [95%CI 56.3-79.7] for the West African subgroup [p=0.0522]. The overall treatment success for all studies was 74.6% [95%CI 65.0-82.2]. We found high heterogeneity among included studies [I 2=96.1%]. The estimated proportion of successfully treated MDR/RR-TB individuals was considerably higher than the global estimate provided by the WHO (59%) reaching the 2015 WHO target of at least 75% treatment success for MDR-TB.

CONCLUSIONS: The use of shorter treatment regimens and the standardized treatment conditions including DOT in these studies could have contributed to a high treatment success. Yet, the available literature was not fully representative of the regions, possibly highlighting the sparse resources in many of these countries. The review was registered at PROSPERO ( (CRC42022350645).

Original languageEnglish
JournalInternational Journal of Infectious Diseases
Publication statusE-pub ahead of print - 22 Aug 2022

Bibliographical note

Copyright © 2022. Published by Elsevier Ltd.

See relations at Aarhus University Citationformats

ID: 281737328